Rituximab and protection from vaccine preventable diseases: applying the evidence to pediatric patients

Expert Review of Vaccines

Volumn 15, Issue 12, 2016, Pages 1567-1574

  Cheng, Daryl R ^a,b,c   Barton, Rebecca ^a   Greenway, Anthea ^a,c   Crawford, Nigel W ^a,b,c  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

Author keywords

immunization; immunogenicity; Pediatrics; rituximab; safety; vaccination; vaccine

Indexed keywords

ANTIGEN; INFLUENZA VACCINE; LIVE VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RITUXIMAB; TETANUS TOXOID; VARICELLA ZOSTER VACCINE; IMMUNOSUPPRESSIVE AGENT; VACCINE;

ANTIBODY TITER; CHILD CARE; DRUG MECHANISM; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; PNEUMOCOCCAL INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; TETANUS; VACCINATION; COMMUNICABLE DISEASES; IMMUNOLOGY; OPPORTUNISTIC INFECTIONS;

COMMUNICABLE DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OPPORTUNISTIC INFECTIONS; RITUXIMAB; VACCINES;

EID: 84996542595     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1080/14760584.2016.1193438     Document Type: Review

References (88)

1. Crawford NW, Bines JE, Royle J, et al. Optimizing immunization in pediatric special risk groups. Expert Rev Vaccines. 2011;10(2):175–186.
2. Arvas A., Vaccination in patients with immunosuppression. Turk Pediatri Ars. 2014;49(3):181–185.
3. Akikusa JD, Crawford NW. Vaccination in paediatric rheumatology. Curr Rheumatol Rep. 2014;16(8):432.
4. Morin MP, Quach C, Fortin E, et al. Vaccination coverage in children with juvenile idiopathic arthritis followed at a paediatric tertiary care centre. Rheumatol (Oxford). 2012;51(11):2046–2050.
5. Moulis G, Lapeyre-Mestre M, Mahevas M, et al. Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France. Am J Hematol. 2015;90(4):301–305.
6. Heijstek MW, Ott de Bruin LM, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70(10):1704–1712.•• Comprehensive European-based guideline set for vaccination for pediatric rheumatological conditions, including those on Rituximab–specifically for pediatric population.
7. Cooper N, Bussel JB. The long-term impact of rituximab for childhood immune thrombocytopenia. Curr Rheumatol Rep. 2010;12(2):94–100.
8. Dai WJ, Zhang RR, Yang XC, et al. Efficacy of standard dose rituximab for refractory idiopathic thrombocytopenic purpura in children. Eur Rev Med Pharmacol Sci. 2015;19(13):2379–2383.
9. Minard-Colin V, Brugières L, Reiter A, et al. Non-Hodgkin lymphoma in children and adolescents:progress through effective collaboration, current knowledge, and challenges ahead. J Clin Oncol. 2015;33(27):2963–2974.
10. Ravani P, Rossi R, Bonanni A, et al. Rituximab in children with steroid-dependent nephrotic syndrome:A multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol. 2015;26(9):2259–2266.
11. Tambralli A, Beukelman T, Cron RQ, et al. Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases. J Rheumatol. 2015;42(3):541–546.
12. Webb H, Jaureguiberry G, Dufek S, et al. Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2015;31(4):589–594.
13. Salzer J, Lycke J, Wickström R, et al. Rituximab in paediatric onset multiple sclerosis:a case series. J Neurol. 2016;263(2):322–326.
14. Choi PY, Roncolato F, Badoux X, et al. A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). Blood. 2015;126(4):500–503.
15. van der Kolk LE, Baars JW, Prins MH, et al. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood. 2002;100(6):2257–2259.• Vaccine response in adult lymphoma patients–showing decreased response in tetanus, polio, KLH.
16. Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol (Orlando, Fla). 2007;122(1):62–74.
17. Bingham CO, 3rd, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab:results from a controlled clinical trial. Arthritis Rheum. 2010;62(1):64–74.•• Largest available adult study on patients using Rituximab for rheumatoid arthritis–showing good response to tetanus but poor response to pneumococcal and KLH.
18. Leandro MJ, Cambridge G, Ehrenstein MR, et al. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(2):613–620.
19. Nakou M, Katsikas G, Sidiropoulos P, et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis:depletion of memory B cells correlates with clinical response. Arthritis Res Ther. 2009;11(4):R131.
20. Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909–920.
21. Rehnberg M, Amu S, Tarkowski A, et al. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther. 2009;11(4):R123.
22. Cioc AM, Vanderwerf SM, Peterson BA, et al. Rituximab-induced changes in hematolymphoid tissues found at autopsy. Am J Clin Pathol. 2008;130(4):604–612.
23. Thurlings RM, Vos K, Wijbrandts CA, et al. Synovial tissue response to rituximab:mechanism of action and identification of biomarkers of response. Ann Rheum Dis. 2008;67(7):917–925.
24. Vos K, Thurlings RM, Wijbrandts CA, et al. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum. 2007;56(3):772–778.
25. Bennett CM, Rogers ZR, Kinnamon DD, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood. 2006;107(7):2639–2642.
26. Wang J, Wiley JM, Luddy R, et al. Chronic immune thrombocytopenic purpura in children:assessment of rituximab treatment. J Pediatr. 2005;146(2):217–221.
27. Taube T, Schmid H, Reinhard H, et al. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica. 2005;90(2):281–283.
28. Oren S, Mandelboim M, Braun-Moscovici Y, et al. Vaccination against influenza in patients with rheumatoid arthritis:the effect of rituximab on the humoral response. Ann Rheum Dis. 2008;67(7):937–941.• Sole study showing adequate vaccine response to influenza in adult rheumatoid arthritis patients on Rituximab.
29. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy:results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793–2806.
30. Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis:an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896–3908.
31. Bisogno G. Persistent B-cell depletion after rituximab for thrombocytopenic purpura. Eur J Pediatr. 2007;166(1):85–86.
32. Gluck T, Muller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis off Publ Infect Dis Soc Am. 2008;46(9):1459–1465.
33. Rao A, Kelly M, Musselman M, et al. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer. 2008;50(4):822–825.
34. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572–2581.
35. van Vollenhoven RF, Emery P, Bingham CO, 3rd, et al. Long-term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010;37(3):558–567.
36. Wilk E, Witte T, Marquardt N, et al. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum. 2009;60(12):3563–3571.
37. Stroopinsky D, Katz T, Rowe JM, et al. Rituximab-induced direct inhibition of T-cell activation. Cancer Immunol Immunother. 2012;61(8):1233–1241.
38. Melet J, Mulleman D, Goupille P, et al. Rituximab-induced T cell depletion in patients with rheumatoid arthritis:association with clinical response. Arthritis Rheum. 2013;65(11):2783–2790.
39. Piantoni S, Scarsi M, Tincani A, et al. Circulating CD4+ T-cell number decreases in rheumatoid patients with clinical response to rituximab. Rheumatol Int. 2015;35(9):1571–1573.
40. Nazi I, Kelton JG, Larche M, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood. 2013;122(11):1946–1953.
41. Cho CH, Hwang WL, Cheng SB, et al. Hepatitis B reactivation induced by Rituximab maintenance therapy for lymphoma. Ann Hematol. 2011;90(1):111–112.
42. Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood. 2009;113(14):3147–3153.
43. Pei SN, Chen CH, Lee CM, et al. Reactivation of hepatitis B virus following rituximab-based regimens:a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol. 2010;89(3):255–262.
44. Tsutsumi Y, Yamamoto Y, Ito S, et al. Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol. 2015;7(21):2344–2351.
45. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients:a report of 57 cases from the research on adverse drug events and reports project. Blood. 2009;113(20):4834–4840.
46. Xanthouli P, Sailer S, Fiehn C. Rituximab (RTX) as an alternative to TNF-Alpha antagonists in patients with rheumatoid arthritis and high risk of severe infections:a systematic analysis of the experience in one center. Open Rheumatol J. 2012;6:286–289.
47. Arnold DM, Dentali F, Crowther MA, et al. Systematic review:efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146(1):25–33.
48. Streif W, Escuriola Ettingshausen C, Linde R, et al. Inhibitor treatment by rituximab in congenital haemophilia A - Two case reports. Hamostaseologie. 2009;29(2):151–154.
49. Quartier P, Tournilhac O, Archimbaud C, et al. Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. Clin Infect Dis off Publ Infect Dis Soc Am. 2003;36(3):e47–e49.
50. Ng PC, Lee KK, Lo AF, et al. Anti B cell targeted immunotherapy for treatment of refractory autoimmune haemolytic anaemia in a young infant. Arch Dis Child. 2003;88(4):337–339.
51. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17(7):1055–1065.
52. Westra J, Rondaan C, van Assen S, et al. Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol. 2015;11(3):135–145.
53. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31(6):456–473.
54. Hua C, Barnetche T, Combe B, et al. Effect of methotrexate, anti-tumor necrosis factor alpha, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis:a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014;66(7):1016–1026.
55. Arad U, Tzadok S, Amir S, et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine. 2011;29(8):1643–1648.
56. Bedognetti D, Zoppoli G, Massucco C, et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin’s lymphoma patients treated with rituximab-containing regimens. J Immunol (Baltimore, Md:1950). 2011;186(10):6044–6055.
57. Eisenberg RA, Jawad AF, Boyer J, et al. Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol. 2013;33(2):388–396.
58. Gelinck LB, Teng YK, Rimmelzwaan GF, et al. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis. 2007;66(10):1402–1403.
59. Kapetanovic MC, Kristensen LE, Saxne T, et al. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res Ther. 2014;16(1):R2.
60. Kim W, Kim SH, Huh SY, et al. Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab. Eur J Neurol. 2013;20(6):975–980.
61. Rehnberg M, Brisslert M, Amu S, et al. Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. Arthritis Res Ther. 2010;12(3):R111.
62. van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010;62(1):75–81.
63. Westra J, van Assen S, Wilting KR, et al. Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. Clin Exp Immunol. 2014;178(1):40–47.
64. Yri OE, Torfoss D, Hungnes O, et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood. 2011;118(26):6769–6771.• Large study looking at response to H1N1 vaccine in rheumatoid arthritis patients using Rituximab, showing lower antibody response compared to controls.
65. Crnkic Kapetanovic M, Saxne T, Jonsson G, et al. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther. 2013;15(5):R171.
66. Albert D, Dunham J, Khan S, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis. 2008;67(12):1724–1731.
67. Berglund A, Willen L, Grodeberg L, et al. The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab. Acta Oncol. 2014;53(9):1212–1220.
68. Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood. 2004;103(3):777–783.
69. Withers DR, Fiorini C, Fischer RT, et al. T cell-dependent survival of CD20+ and CD20- plasma cells in human secondary lymphoid tissue. Blood. 2007;109(11):4856–4864.
70. MacIntyre R, Stein A, Harrison C, et al. Increasing trends of herpes zoster in Australia. PLoS One. 2015;10(4):e0125025.
71. Bearden CM, Agarwal A, Book BK, et al. Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transpl Offi J Am Soc Transpl Am Soc Transpl Surg. 2005;5(1):50–57.
72. National Institutes of Health. Clinicaltrials.gov - Search Results 2016 Available from:https://clinicaltrials.gov/ct2/results?term=rituximab+vaccine&recr=&rslt=&type=&cond=&intr=&titles=&outc=&spons=&lead=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&age=0&rcv_s=&rcv_e=&lup_s=&lup_e=.
73. Heijstek MW, van Gageldonk PG, Berbers GA, et al. Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls:a retrospective cross-sectional study. Ann Rheum Dis. 2012;71(6):948–954.
74. National Health and Medical Research Council (NHMRC). Australian Immuniation Handbook - Vaccination for Special Risk Groups 2014 [10th edition. Available from:http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home~handbook10part3.
75. National Health and Medical Research Council (NHMRC) Australian Immunization Handbook - Q Fever 2014. Available from:http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home~handbook10part4~handbook10-4-15.
76. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009;361(22):2143–2152.
77. Cambridge G, Leandro MJ, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus:effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 2006;54(11):3612–3622.
78. Papadopoulou D, Sipsas NV. Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases. Rheumatol Int. 2014;34(2):151–163.
79. Kobayashi I, Mori M, Yamaguchi K, et al. Pediatric rheumatology association of Japan recommendation for vaccination in pediatric rheumatic diseases. Mod Rheumatol. 2015;25(3):335–343.•• Comprehensive Japanese-based guideline set for vaccination for pediatric rheumatological conditions, including those on Rituximab–specifically for pediatric population.
80. Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy:risk and prophylaxis recommendations. World J Gastroenterol. 2015;21(36):10274–10289.
81. Mok CC. Rituximab for the treatment of rheumatoid arthritis:an update. Drug Des Devel Ther. 2014;8:87–100.
82. Burr ML, Malaviya AP, Gaston JH, et al. Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis. Rheumatol (Oxford). 2008;47(5):738–739.
83. Jung N, Owczarczyk K, Hellmann M, et al. Efficacy and safety of rituximab in a patient with active rheumatoid arthritis and chronic disseminated pulmonary aspergillosis and history of tuberculosis. Rheumatol (Oxford). 2008;47(6):932–933.
84. Pehlivan Y, Kisacik B, Bosnak VK, et al. Rituximab seems to be a safer alternative in patients with active rheumatoid arthritis with tuberculosis. BMJ Case Rep. 2013;2013:pii:bcr2012006585. doi:10.1136/bcr-2012-006585. [Epub ahead of print]
85. Sidner RA, Book BK, Agarwal A, et al. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies. 2004;13(3):55–62.
86. St. Clair EW. Good and bad memories following rituximab therapy. Arthritis Rheum. 2010;62(1):1–5.
87. Crawford NW, Heath JA, Ashley D, et al. Survivors of childhood cancer:an Australian audit of vaccination status after treatment. Pediatr Blood Cancer. 2010;54(1):128–133.
88. Compagno N, Cinetto F, Semenzato G, et al. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia:a single-center experience in 61 patients. Haematologica. 2014;99(6):1101–1106.